As discussed in the checkpoint inhibitor section, most of the biomarker literature to date comes from studies of PD-1/PD-L1 blockade, often extrapolated from non-PTCL contexts, and includes factors such as PD-L1 expression, EBV status, tumor mutational burden, and 9p24.1 structural variants. Here, CD274 is linked to neoplasm.